Recent Acquisition Peak Proteins was acquired by Sygnature Discovery in June 2022, indicating increased integration with a broader drug discovery platform, potentially opening opportunities for collaborative projects and expanded service offerings.

Service Expansion The company launched a protein mass spectrometry service in May 2019, demonstrating a commitment to broadening its analytical capabilities, which could present upsell opportunities to existing clients requiring comprehensive structural and analytical protein solutions.

Industry Focus Specializing in structure-based drug discovery and protein science, Peak Proteins serves biotech and pharma companies engaged in high-throughput screening, assay development, and structure-based design, aligning with client needs for bespoke protein production.

Operational Scale With a team of 11-50 employees and revenue ranging between 1M to 10M USD, Peak Proteins is positioned as a nimble and specialized partner capable of delivering timely, tailored protein solutions, ideal for clients seeking personalized research collaborations.

Market Opportunities As part of Sygnature's integrated drug discovery efforts, Peak Proteins has access to a strong network within the biotech sector, providing avenues to introduce complementary products or services like structural biology, biophysical assays, and custom protein production.